According to Viking Therapeutics
's latest financial reports the company has $0.96 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $0.36 B | 132.87% |
2022-12-31 | $0.15 B | -23.07% |
2021-12-31 | $0.20 B | -18.63% |
2020-12-31 | $0.24 B | -9.89% |
2019-12-31 | $0.27 B | -8.58% |
2018-12-31 | $0.30 B | 1365.47% |
2017-12-31 | $20.57 M | 56.46% |
2016-12-31 | $13.15 M | -6.76% |
2015-12-31 | $14.1 M | 1765.97% |
2014-12-31 | $0.75 M | 320.81% |
2013-12-31 | $0.17 M | |
2012-12-31 | $N/A |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Ultragenyx RARE | $0.57 B | -40.06% | ๐บ๐ธ USA |
Repligen
RGEN | $0.78 B | -18.94% | ๐บ๐ธ USA |
Recro Pharma
REPH | N/A | N/A | ๐บ๐ธ USA |